Skip to main content

Table 2 Health outcomes among HCV patients and controls

From: The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries

  HCV group Unmatched controls Matched controls
  (n = 286) (n = 56,880) (n = 286)
  Mean SD Mean SD p-value* Mean SD p-value†
Work impairment
 Absenteeism 7.78% 19.16% 5.44% 19.20% <.001 5.45% 20.34% .010
 Presenteeism 26.27% 27.58% 15.83% 22.79% <.001 14.45% 21.58% <.001
 Overall work impairment 30.45% 31.42% 19.39% 27.70% <.001 18.30% 27.47% <.001
Activity impairment 34.37% 30.60% 24.38% 28.16% <.001 28.46% 30.57% .011
Healthcare use
 Annual physician visits 19.80 23.93 10.66 14.64 <.001 13.26 19.21 <.001
 Annual ER visits 0.68 2.11 0.38 1.90 .006 0.39 1.19 .330
 Annual hospitalizations 0.52 1.59 0.26 2.14 <.001 0.27 0.98 .073
Quality of life (SF-12v2)
 MCS 44.17 9.85 46.58 10.59 <.001 46.36 10.79 .012
 PCS 43.61 10.14 48.67 9.75 <.001 46.09 10.33 .004
 Health utility 0.67 0.12 0.73 0.13 <.001 0.71 0.15 .001
  1. Comparisons of work impairment include only the employed subsamples: 138 HCV patients, 32,179 non-HCV, and 134 matched controls.
  2. *Indicates the significance comparing the HCV group with the unmatched control group.
  3. †Indicates the significance comparing the HCV group with the matched control group.